AIOS at-cost wedge in Europe

At cost pricing matters most when the drug itself is already a known national commodity. In markets like the UK, branded GLP-1 prices sit in a relatively tight private pay band, so a telehealth seller cannot win by inventing a premium story around the medication. It wins by being the cheapest compliant path to the same pen, while using shared software and clinical ops to keep service costs low across countries.

• The UK shows the mechanics clearly. Private Wegovy is commonly sold around £199 to £229 per month at Boots, while Numan has been listed around £149 to £299 by dose. Bolt has advertised starter pricing from £99 and maintenance pricing well below many incumbents, which turns price into a simple consumer decision instead of a brand decision.
  1 boltpharmacy 4 boltpharmacy 5 boltpharmacy 6 boltpharmacy
• This wedge is sharper in Europe than in the US because branded list prices are more visibly anchored country by country. AIOS can buy a local licensed pharmacy, plug it into ClinicOS, and reuse the same intake, prescribing, refill, and retention workflow, while only adding local compliance and pharmacy overhead in each new market.
  2 sacra 3 sacra
• The tradeoff is lower gross margin today. The current model passes most drug revenue through to Novo Nordisk and Eli Lilly, with roughly 20% gross margins on branded fulfillment versus the much higher margins Ro and Hims & Hers earn on broader telehealth and fulfillment stacks. That makes scale and operating efficiency more important than markup.
  2 sacra 7 hims 8 sacra

The next step is turning price leadership into a pan European operating system for obesity care. If AIOS can plant a licensed pharmacy in each large market before bigger US entrants fully localize, it can lock in patient acquisition, refill behavior, and clinical workflow first, then capture more of the economics later as generic semaglutide opens up in the early 2030s.